专家共识声明：利奈唑胺的治疗药物监测与个体化用药
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid.
机构信息
Department of Pharmacy, Changxing People's Hospital, Changxing Branch, Second Affiliated Hospital of Zhejiang University School of Medicine, Huzhou, China.
Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Huzhou, China.
出版信息
Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. eCollection 2022.
Abstract
Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.
摘要
利奈唑胺是一种恶唑烷酮类抗菌药物，自批准以来，其治疗药物监测和个体化治疗一直受到挑战。随着利奈唑胺的深入临床研究，我们改变了对其治疗药物监测的态度和个体化治疗的看法。在总结现有临床研究的基础上，根据每位专家在各自专业领域的实践经验，我们形成了本专家共识。我们的专家组是一个多学科团队，包括药剂师、临床药理学专家、重症医学专家、呼吸科专家、传染病专家、急诊医学专家等。我们致力于确保需要的患者安全有效地使用利奈唑胺，并促进其治疗药物监测。
相似文献
1
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid.专家共识声明：利奈唑胺的治疗药物监测与个体化用药
Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. eCollection 2022.
2
Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.抗菌药物的药物监测与个体化剂量优化：恶唑烷酮类
Expert Opin Drug Metab Toxicol. 2016 May;12(5):533-44. doi: 10.1517/17425255.2016.1166204. Epub 2016 Mar 28.
3
Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.利奈唑胺、替地唑胺及其他恶唑烷酮类药物的药物相互作用与安全性
Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12.
4
Oxazolidinone antimicrobials: a patent review (2012-2015).恶唑烷酮类抗菌药物：专利综述（2012 - 2015年）
Expert Opin Ther Pat. 2016 May;26(5):591-605. doi: 10.1517/13543776.2016.1168807. Epub 2016 Apr 4.
5
Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones.强效新型基于利奈唑胺的恶唑烷酮类化合物的抗菌特性及计算分析
Pharmaceuticals (Basel). 2023 Mar 30;16(4):516. doi: 10.3390/ph16040516.
6
A validated UPLC-MS/MS method for the analysis of linezolid and a novel oxazolidinone derivative (PH027) in plasma and its application to tissue distribution study in rabbits.一种经过验证的超高效液相色谱-串联质谱法，用于分析血浆中的利奈唑胺和一种新型恶唑烷酮衍生物（PH027）及其在兔组织分布研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:89-96. doi: 10.1016/j.jchromb.2016.11.034. Epub 2016 Nov 27.
7
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.利奈唑胺在住院儿科患者中的药代动力学/药效学评价：通过治疗药物监测和蒙特卡罗模拟实现剂量优化的一步。
J Antimicrob Chemother. 2015 Jan;70(1):198-206. doi: 10.1093/jac/dku337. Epub 2014 Sep 1.
8
The discovery of linezolid, the first oxazolidinone antibacterial agent.利奈唑胺的发现，首个恶唑烷酮类抗菌剂。
Curr Drug Targets Infect Disord. 2001 Aug;1(2):181-99. doi: 10.2174/1568005014606099.
9
Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class.恶唑烷酮类药物是否名副其实？该抗菌药物类别的未来展望。
Curr Opin Investig Drugs. 2003 Feb;4(2):149-55.
10
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
引用本文的文献
1
Cutaneous nocardiosis in chronic renal insufficiency: Diagnostic and therapeutic considerations.慢性肾功能不全患者的皮肤诺卡菌病：诊断与治疗考量
World J Clin Cases. 2025 Sep 16;13(26):108211. doi: 10.12998/wjcc.v13.i26.108211.
2
Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.肾功能对老年患者中利奈唑胺的血药浓度及血液学毒性的影响：一项倾向匹配队列分析。
BMC Geriatr. 2025 Aug 6;25(1):597. doi: 10.1186/s12877-025-06241-9.
3
Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.利奈唑胺在儿童中的药代动力学和血液学毒性：一项前瞻性、双中心队列研究。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0029425. doi: 10.1128/aac.00294-25. Epub 2025 Jul 23.
4
Web-based automated therapeutic drug monitoring application for precision medicine in tuberculosis management.用于结核病管理中精准医疗的基于网络的自动化治疗药物监测应用程序。
Transl Clin Pharmacol. 2025 Jun;33(2):51-65. doi: 10.12793/tcp.2025.33.e9. Epub 2025 Jun 27.
5
Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.使用通用型与品牌型利奈唑胺治疗的患者血小板减少症发生率的比较分析：一项利用医院电子病历的队列研究。
Front Pharmacol. 2025 Jun 18;16:1528633. doi: 10.3389/fphar.2025.1528633. eCollection 2025.
6
Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics.基于群体药代动力学的帕罗西汀对奥氮平的药物相互作用及重度抑郁症患者初始剂量优化
Front Psychiatry. 2025 May 13;16:1538996. doi: 10.3389/fpsyt.2025.1538996. eCollection 2025.
7
High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia.肝功能和肾功能不全患者血清中利奈唑胺及其主要代谢产物的高蓄积与血小板减少症和贫血显著相关。
Microbiol Spectr. 2025 Jul;13(7):e0249324. doi: 10.1128/spectrum.02493-24. Epub 2025 May 19.
8
Effective Management of a Skin and Soft Tissue Infection Caused by Community-Acquired MRSA Through Triple-Targeted Therapy Along with Aggressive Source Control: A Case Report.通过三联靶向治疗及积极的源头控制有效管理社区获得性耐甲氧西林金黄色葡萄球菌引起的皮肤和软组织感染：一例报告
Infect Dis Rep. 2025 Mar 24;17(2):27. doi: 10.3390/idr17020027.
9
Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis.利奈唑胺和特地唑胺的不良反应：关于血清素综合征、骨髓抑制、神经病变和乳酸性酸中毒的综述
Antimicrob Steward Healthc Epidemiol. 2025 Jan 27;5(1):e20. doi: 10.1017/ash.2024.487. eCollection 2025.
10
Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency.利奈唑胺治疗肾功能不全医院获得性肺炎患者的群体药动学/药效学研究。
Drug Des Devel Ther. 2024 Nov 8;18:5073-5086. doi: 10.2147/DDDT.S474470. eCollection 2024.
本文引用的文献
1
UPLC-MS/MS Determination of Linezolid and Heme in Plasma of Infected Patients and Correlation Analysis.UPLC-MS/MS 测定感染患者血浆中的利奈唑胺和血红素及相关性分析。
Biomed Res Int. 2021 Jul 10;2021:6679076. doi: 10.1155/2021/6679076. eCollection 2021.
2
Simultaneous Measurement of 11 Antibiotics for Use in the Intensive Care Unit by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.采用超高效液相色谱-串联质谱法同时测定重症监护病房中 11 种抗生素的浓度。
Ther Drug Monit. 2022 Apr 1;44(2):308-318. doi: 10.1097/FTD.0000000000000911.
3
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.肾功能对利奈唑胺治疗患者血小板减少症风险的影响：系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 Feb;88(2):464-475. doi: 10.1111/bcp.14965. Epub 2021 Oct 10.
4
Liver function, quantified by the LiMAx test, as a predictor for the clinical outcome of critically ill patients treated with linezolid.通过LiMAx试验量化的肝功能，作为接受利奈唑胺治疗的重症患者临床结局的预测指标。
Technol Health Care. 2022;30(2):309-321. doi: 10.3233/THC-191847.
5
Linezolid resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Iran.伊朗耐多药结核分枝杆菌临床分离株中的利奈唑胺耐药性
Acta Microbiol Immunol Hung. 2021 Jun 24. doi: 10.1556/030.2021.01490.
6
Trend in Antimicrobial Resistance of : Results from the China Antimicrobial Surveillance Network (CHINET) in the Last 15-Year-Period Reports (2005-2019).抗菌药物耐药性趋势：中国抗菌药物监测网（CHINET）过去15年（2005 - 2019年）报告结果
Infect Drug Resist. 2021 Jun 10;14:2179-2181. doi: 10.2147/IDR.S318005. eCollection 2021.
7
Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.初始降低利奈唑胺给药方案以预防血液透析患者血小板减少症。
Antibiotics (Basel). 2021 Apr 26;10(5):496. doi: 10.3390/antibiotics10050496.
8
Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.利奈唑胺的剂量个体化：优化利奈唑胺疗效并最大程度降低毒性的精准剂量。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02490-20.
9
Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.利奈唑胺在肾功能损害患者中的初始和维持剂量方案的建议。
BMC Pharmacol Toxicol. 2021 Mar 4;22(1):13. doi: 10.1186/s40360-021-00479-w.
10
Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia.基于机器学习的利奈唑胺诱导血小板减少症预测的分类树分析。
J Pharm Sci. 2021 May;110(5):2295-2300. doi: 10.1016/j.xphs.2021.02.014. Epub 2021 Feb 17.
Zotero 插件